DxS Ltd - Unquoted

DxS is a leading provider of genetic analysis services to pharmaceutical companies and contract research organisations. The company's services include the provision of genetic testing using single nucleotide polymorphism technology and DNA extraction and banking. DxS's services are of particular use to pharmaceutical companies when they are conducting clinical trials as the genomic tests can be used to help identify groups of patients that are most likely to benefit from a particular therapy. David Evans, who is chairman of a number of AIM-quoted companies (including BBI Holdings plc and Epistem Holdings plc, both Hygea investee companies) became chairman of DxS in 2006.

NEWS
In September 2009, DxS was acquired by Qiagen, resulting in Hygea receiving initial cash proceeds of £3.6 million, with entitlement to receive up to a further £2.5 million over the period to 2012 subject to the achievement by DxS of specified objectives.

 

Links:
DxS

Last Updated: 24/07/2018

Investment Information:
date of first inv: Apr 2004
cost: £325,000
valn at: 30/06/2018 £n/a (see text)
equity held: 8.3%